The broader impact of this Small Business Innovation Research (SBIR) Phase II project lies in advancing the development of CATOS-AI (Cancer Treatment Optimization Solutions – Artificial Intelligence) towards integration with healthcare-IT systems, paving the way for commercialization after completing key milestones in the Phase I project. By leveraging a strong collaboration between academia and industry experts, this project aims to enhance the global competitiveness of this innovative technology, addressing a critical need in precision oncology. The anticipated outcomes include substantial improvements in personalized cancer care and accelerated development of new drug options, leading to better survival rates for cancer patients while reducing time and costs. Additionally, the software is expected to benefit millions of cancer patients by improving the quality of care, supporting pharmaceutical research and development, and alleviating the overall healthcare burden. This Small Business Innovation Research (SBIR) Phase II project aims to build a powerful artificial intelligence (AI) based clinical decision-making tool called CATOS-AI (Cancer Treatment Optimization Solutions – Artificial Intelligence) for personalized cancer care. Addressing the need for advanced AI solutions in precision oncology and drug repositioning, the project will utilize machine learning and multi-omics analysis to discover new drugs or repurpose existing ones for treating non-small cell lung can